Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00645541 · ClinicalTrials.gov registry record · Phase 1
Axillary Reverse Mapping for Invasive Carcinoma of the Breast
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00645541: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00645541 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00645541, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
Primary Objectives: * To determine the feasibility of axillary reverse mapping (ARM) in patients undergoing axillary lymph node dissection for breast cancer therapy. * To determine the incidence of breast cancer metastasis in lymph nodes draining in the arm as identified by axillary reverse mapping. * To determine the safety of axillary reverse mapping.
Interventions
- PROCEDURE Axillary Reverse Mapping
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00645541
The ClinicalTrials.gov registry entry for NCT00645541 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Axillary Reverse Mapping is the first listed.
NCT00645541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00645541 about?
NCT00645541 is a clinical study titled "Axillary Reverse Mapping for Invasive Carcinoma of the Breast". Primary Objectives: * To determine the feasibility of axillary reverse mapping (ARM) in patients undergoing axillary lymph node dissection for breast cancer therapy. * To determine the incidence of breast cancer metastasis in lymph nodes draining in the arm as identified by axillary reverse mapping...
What is the current status of trial NCT00645541?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2008-03. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00645541?
The interventions under investigation include: Axillary Reverse Mapping (PROCEDURE).
Who is sponsoring clinical trial NCT00645541?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.